基因總覽
SYNJ1 是蛋白質編碼基因，產物 synaptojanin 1 屬於 synaptojanin 家族；其中段亦歸入 inositol 1,4,5-trisphosphate 5-phosphatase 家族。蛋白質長 1573 個胺基酸，具有 SAC、5-PPase 與 RRM 等功能區，並含有多段預測為無序的區域。其多個功能區共同構成可作用於不同磷酸肌醇底物的酵素架構，這些結構特色提供其參與細胞膜脂質代謝與突觸相關過程的分子基礎。
基因異名與舊稱
異名取自 HGNC，可能包含歷史名稱；蛋白質名稱以 UniProt 註解為準。
染色體位置與基因結構
查看實際轉錄本與 exon 註解
| Transcript | Genomic coordinates | Exons |
|---|---|---|
| ENST00000674351 ★ | 32,628,763–32,728,013 | 33 |
| ENST00000630077 | 32,628,756–32,727,967 | 28 |
| ENST00000674308 | 32,628,756–32,728,013 | 32 |
| ENST00001034287 | 32,628,756–32,728,395 | 28 |
| ENST00001075151 | 32,628,756–32,728,395 | 28 |
| ENST00000902244 | 32,628,757–32,727,967 | 31 |
| ENST00000963072 | 32,628,758–32,728,395 | 31 |
| ENST00000382491 | 32,628,759–32,728,395 | 29 |
| ENST00000438952 | 32,628,763–32,645,710 | 8 |
| ENST00000674204 | 32,628,763–32,727,921 | 33 |
| ENST00000357345 | 32,628,763–32,727,967 | 32 |
| ENST00000418301 | 32,631,778–32,641,945 | 5 |
顯示 12/18 個蛋白質編碼轉錄本；canonical 優先。
帶型與著絲點依 Ensembl 座標繪製；核染色體長度以 GRCh38 第 1 號染色體為共同尺度。黃色標記表示本基因位置，細小區間加粗以利辨識；實際基因長度與 exon 見下方資料。
分子功能與生物學過程
synaptojanin 1 是磷酸酶，依不同功能區從磷酸肌醇與肌醇磷酸的肌醇環上水解特定磷酸基。5-PPase domain 移除底物的 5 位磷酸基，作用對象包括 PtdIns(4,5)P2、PtdIns(3,4,5)P3、Ins(1,4,5)P3 與 Ins(1,3,4,5)P4。SAC domain 則可水解肌醇環 3 位或 4 位的磷酸基，底物包括 PI(3)P、PI(4)P 與 PI(3,5)P2。這種由不同區域分工處理多種底物的特性，參與調節細胞內磷酸肌醇的組成。
在超快速內吞作用中，synaptojanin 1 參與新形成突觸小泡的快速頸部形成；此作用被描述為透過其磷酸肌醇 5-磷酸酶活性進行。這項角色依據相似性推定。超快速內吞後，突觸小泡也可由突觸內體出芽形成；synaptojanin 1 透過其磷酸酶功能區的共同作用，參與這類小泡的 clathrin 去包被。此項突觸小泡相關作用同樣標示為依相似性推定。
此外，synaptojanin 1 可水解與 actin 調節蛋白結合的 PIP2，進而調節 actin filament 的重排；此功能亦屬依相似性推定。合併來看，來源支持其磷酸酶活性與突觸小泡形成、去包被及 actin 絲重排相關，但其中內吞與 actin 調節的描述帶有相似性推論性質。
Promoter 與基因調控
>SYNJ1 ENST00000674351 GRCh38 chr21:32727913-32729013 strand=-1 5′→3′ 相對 TSS：-1000 到 +100 bp；1101 bp 依轉錄本 TSS 擷取的基因組序列；TSS = 0，兩端包含，未驗證為 promoter GCAACATAACCAAATTTAAATCCTGCTTTGGCTGTTGAAAACCAGAAGGAGAAGAGGTAAAGAAAAAGCA AACGCAAGTGGAGACAGTTTGAGTGCTGGGTTCTTCAGGTTTTCAATTTCTTTCTGCCCTGTTGGCTTTG ACTTCATTCTCTTTCTTATTAGGTCTATTCAATGGAAGCAGAAATCTATGGGACACGCTGATATTAGCCA GGAAGCACCATTTGTTGAAAAATGAGGATGAGATAAAAGGGTTAGGTGCCTTTAGTTACTAAATTCCACG GTTGGCAAAAGCTATTCATCCGTCGGTGACAACCACAGCTGTCGTGGCCTCCCTACGGCCATGTTTTGTT GGACTCAGCCTTGAGATCCTGGTTTGTGACGTCCCACTCTCCATCGTATACACCTAAGCACTCTTCGATA GAACCCTGTGAGCTCCAGAACACACAAGAAAAGGCACCGAACAGAACTGTCCCAGAGCAGGCATTAGTTT TTCTTCTGCTACCTATCCAGACACTCAGACTAGGAACTCGGTGCCGTTTGCTGGGCTGTCGACACCATGG ACAGCTCTTCAGGCGCCACCTGGTTGGCTCGGCGAGCCGACCGTCCCGAGCCCTTCCTCCTCTCCCGTCA GGCCCGTGGGGGCGGCGGGGTTGGTCCTGACGCCCAGCTTGGGGAGCAGCAATACGCAGCCCCCCAAGCT TTTCTCCGGAGTCCCTCCCCGGCGCTCACGCTCTGAAGAGCCCACGCAAAAGGACCAAGGAGGCCAGATC TTCCCTCTCCCTGCACCCCCGGCGGTGGGATCGCAGCTCTGCCTGGGGGCGGCCGCAGGAGGCAAAGGTA GCTGGAGACTGAGGCTGGGGCCGCCCGCGGGTGCCAGGCCCAGCCGGTCGGCGCAGAGTGGGCGTGGTCT CCCTCCTGATGCCCCGCCCCTTCCCTCGCGCGGGGCGGATCTTCCGCCCCCGGCCGCGGCGCAATGCGGA AGAGATGGGCCTGCTGGAGCGGAAGTGACGCTCCCGGCGGCTGTGGCGGCGGCTGCGGGAGAAGGAGGAG GAGGAGCCGGAGGAAGAGGTGAGCAAGCCGGCGGGGGGCGGGGAGCTGCTG
EPDnew 實驗支持 promoter／TSS · 3 筆
| EPDnew ID | TSS（1-based） | 股向 | 來源顯示區間 |
|---|---|---|---|
| SYNJ1_1 ↗ | 21:32,727,907 | 負股 | 32,727,897–32,727,956 |
| SYNJ1_3 ↗ | 21:32,728,013 | 負股 | 32,728,003–32,728,062 |
| SYNJ1_2 ↗ | 21:32,728,394 | 負股 | 32,728,384–32,728,443 |
EPDnew human v006 · UCSC hg38，GRCh38/hg38，透過 UCSC 取得。TSS 具有 CAGE／RAMPAGE 等實驗資料支持；任意擷取的上下游區間仍需另行判讀調控功能，不能視為整段皆經功能驗證。
EPD 封存狀態 ↗ · UCSC 資料說明 ↗ · EPD team, SIB Swiss Institute of Bioinformatics; UCSC Genome Browser · CC BY 4.0
查看已取得的調控／motif 註解
ENSR21_B8HCZ · promoter · 32727911–32728610 · regulatory
ENSR21_59NSTJ · CTCF_binding_site · 32728424–32728445 · regulatory
ENSR21_9GZQ6 · enhancer · 32728611–32729118 · regulatory
· motif · 32727026–32727041 · motif
· motif · 32727726–32727743 · motif
· motif · 32727735–32727750 · motif
· motif · 32728007–32728016 · motif
· motif · 32728007–32728018 · motif
· motif · 32728030–32728041 · motif
· motif · 32728030–32728043 · motif
· motif · 32728048–32728061 · motif
· motif · 32728083–32728093 · motif
· motif · 32728106–32728116 · motif
· motif · 32728108–32728121 · motif
· motif · 32728264–32728277 · motif
· motif · 32728368–32728378 · motif
· motif · 32728426–32728442 · motif
· motif · 32728689–32728702 · motif
· motif · 32728689–32728702 · motif
蛋白質結構域與序列
參考蛋白質長度：1573 aa
synaptojanin 1 長 1573 個胺基酸，含 SAC、5-PPase 與 RRM 功能區；其中 5-PPase domain 位於蛋白質中央區段。序列另有多段預測為無序的區域，並包含三組 N-P-F 重複序列。
蛋白質三維結構
細胞內定位
synaptojanin 1 位於細胞質、核周區域、突觸前區與膜；在神經末梢會集中於 clathrin 包被的內吞中間體，也會被募集至同時帶有 clathrin 與 dynamin 包被的中間體。
深綠色圓點：來源記載的蛋白質定位；數量不表示含量。
未繪示構造：Presynapse；Membrane。這些構造未在通用細胞圖中標點，仍保留來源定位名稱。
動物細胞結構示意；器官大小與數量不按比例。點選細胞構造可查看定位註解。
交互作用與訊號網絡
拖曳節點後放開可帶動位置變化；點選夥伴查看證據。位置與連線長度不代表結合強度，圖中未推定夥伴彼此之間的關係。
更多交互作用夥伴 · 已取得 1 個夥伴
- ITSN1Q15811 · UniProt INTERACTION · 2 experiments
synaptojanin 1 與 ASH/GRB2、PACSIN1、PACSIN2、PACSIN3、AMPH、SH3GL1、SH3GL2、SH3GL3、MYO1E、BIN1、DNM1 及 EPS15 有互作記錄。來源指出其透過 SH3 domain 與 MYO1E 互作；PACSIN 蛋白、BIN1、DNM1、EPS15 的互作依相似性推定。資料未進一步說明這些關係是否形成特定複合體。
疾病與遺傳關聯
SYNJ1 變異與早發型 Parkinson disease 20（PARK20）及 Developmental and epileptic encephalopathy 53（DEE53）相關。PARK20 為年輕成人起病的巴金森症候群，可伴隨癲癇、認知退化、眼球運動異常或肌張力不全；DEE53 則為嚴重早發癲癇的一種，遺傳方式為體染色體隱性。來源將兩者列為受此基因變異影響的疾病，並未在此提供特定變異或機制的細節。
Contextual Functional Evidence Matrix
矩陣以「功能主張」為列，以細胞情境、干預條件、量測結果與證據來源為欄，方便比較同一功能在不同條件下的支持情形。只有含情境與實驗資訊的紀錄會列入矩陣；一般功能註解另列於下方。
功能註解總覽 · 17 筆
| 功能面向 | 功能敘述 | 證據類型 | 可查核來源 |
|---|---|---|---|
| 功能 | synaptojanin 1 是磷酸酶，依功能區從磷酸肌醇及肌醇磷酸的肌醇環水解磷酸基。5-PPase domain 移除 5 位磷酸基，底物包括 PtdIns(4,5)P2、PtdIns(3,4,5)P3、Ins(1,4,5)P3 與 Ins(1,3,4,5)P4；SAC domain 則作用於 3 或 4 位，底物包括 PI(3)P、PI(4)P 與 PI(3,5)P2。它依相似性被認為參與超快速內吞時新生突觸小泡的頸部形成，以及其後突觸小泡的 clathrin 去包被；也依相似性被認為可透過水解 actin 調節蛋白結合的 PIP2，調節 actin filament 重排。 | 含實驗來源 | 證據與來源Phosphatase that hydrolyzes phosphate groups from the inositol ring of phosphoinositides and inositol phosphates, in a domain-specific manner. The 5-PPase domain catalyzes removal of the 5-phosphate from substrates such as phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3), inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol-1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4). The SAC domain hydrolyzes phosphates at the 3- and 4-positions of the inositol ring, targeting phosphatidylinositol-3-phosphate (PI(3)P), phosphatidylinositol-4-phosphate (PI(4)P), and phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2). Plays a role in the phosphatidylinositol metabolic process during an unconventional endocytic mechanism, the ultrafast endocytosis where it participates in the rapide neck formation of the newly generated synaptic vesicle through its phosphoinositide 5-phosphatase activity (By similarity). Also, participates in the clathrin uncoating of synaptc vesicle formed via budding from synaptic endosomes after ultrafast endocytosis through combined activity of its phosphatase domains (By similarity). Additionally, regulates actin filament rearrangement by hydrolyzing PIP2 bound to actin regulatory proteins (By similarity) PMID 10224048 ↗ · PMID 18093523 ↗ · PMID 23804563 ↗ · PMID 27435091 ↗ · PMID 33349335 ↗ · PMID 40969890 ↗ |
| 分子活性 | a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate | 含實驗來源 | 證據與來源a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate PMID 10224048 ↗ · PMID 18093523 ↗ · PMID 23804563 ↗ |
| 分子活性 | a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate | 含實驗來源 | 證據與來源a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate PMID 10224048 ↗ · PMID 18093523 ↗ · PMID 23804563 ↗ · PMID 27435091 ↗ |
| 分子活性 | 1,2-dioctanoyl-sn-glycero-3-phospho-(1-D-myo-inositol-4-phosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate | 含實驗來源 | 證據與來源1,2-dioctanoyl-sn-glycero-3-phospho-(1-D-myo-inositol-4-phosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate PMID 27435091 ↗ |
| 分子活性 | a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,5-bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + phosphate | 含實驗來源 | 證據與來源a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,5-bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + phosphate PMID 10224048 ↗ |
| 分子活性 | a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + phosphate | 含實驗來源 | 證據與來源a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + phosphate PMID 18093523 ↗ · PMID 23804563 ↗ · PMID 27435091 ↗ · PMID 33349335 ↗ |
| 分子活性 | 1D-myo-inositol 1,4,5-trisphosphate + H2O = 1D-myo-inositol 1,4-bisphosphate + phosphate | 含實驗來源 | 證據與來源1D-myo-inositol 1,4,5-trisphosphate + H2O = 1D-myo-inositol 1,4-bisphosphate + phosphate PMID 33349335 ↗ · PMID 40969890 ↗ |
| 分子活性 | 1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,3,4-trisphosphate + phosphate | 推論支持 | 證據與來源1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,3,4-trisphosphate + phosphate |
| 分子活性 | a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate | 含實驗來源 | 證據與來源a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate PMID 27435091 ↗ · PMID 33349335 ↗ |
| 分子活性 | 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate | 含實驗來源 | 證據與來源1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate PMID 27435091 ↗ · PMID 33349335 ↗ · PMID 40969890 ↗ |
| 分子活性 | a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate | 含實驗來源 | 證據與來源a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate PMID 33349335 ↗ |
| 分子活性 | 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate | 含實驗來源 | 證據與來源1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate PMID 33349335 ↗ |
| 分子活性 | 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1-D-myo-inositol-4-phosphate) + phosphate | 含實驗來源 | 證據與來源1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1-D-myo-inositol-4-phosphate) + phosphate PMID 27435091 ↗ · PMID 33349335 ↗ |
| 交互作用 | synaptojanin 1 與 ASH/GRB2、PACSIN1、PACSIN2、PACSIN3、AMPH、SH3GL1、SH3GL2、SH3GL3、MYO1E、BIN1、DNM1 及 EPS15 有互作記錄。它透過 SH3 domain 與 MYO1E 互作；與 AMPH、SH3GL1、SH3GL2、SH3GL3 的互作有文獻支持，而 PACSIN 蛋白、BIN1、DNM1、EPS15 的互作則依相似性推定。 | 含實驗來源 | 證據與來源Interacts with ASH/GRB2. Interacts with PACSIN1, PACSIN2 and PACSIN3 (By similarity). Interacts with AMPH, SH3GL1, SH3GL2 and SH3GL3. Interacts with MYO1E (via SH3 domain). Interacts with BIN1 and DNM1 (By similarity). Interacts with EPS15 (By similarity) PMID 10542231 ↗ · PMID 17257598 ↗ · PMID 18093523 ↗ |
| 細胞定位 | synaptojanin 1 位於細胞質、核周區域、突觸前區與膜。在神經末梢，它會集中於 clathrin 包被的內吞中間體，並會被募集至同時帶有 clathrin 與 dynamin 包被的中間體。 | 含實驗來源 | 證據與來源Cytoplasm, perinuclear region; Presynapse; Membrane; Concentrates at clathrin-coated endocytic intermediates in nerve terminals. Also recruited to clathrin- and dynamin-coated intermediates PMID 18093523 ↗ |
| 疾病關聯 | SYNJ1 變異與早發型 Parkinson disease 20（PARK20）相關，患者於年輕成人期出現巴金森症候群。疾病可見動作遲緩、靜止性顫抖、肌肉僵硬與姿勢不穩，並可能伴隨癲癇、認知退化、眼球運動異常或肌張力不全；典型病理涉及黑質多巴胺神經元流失及存活神經元中的 Lewy bodies。來源指出疾病由影響該基因的變異所致。 | 含實驗來源 | 證據與來源Parkinson disease 20, early-onset PARK20 An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK20 is characterized by young adult-onset of parkinsonism. Additional features may include seizures, cognitive decline, abnormal eye movements, and dystonia. The disease is caused by variants affecting the gene represented in this entry MIM: 615530 PMID 23804563 ↗ · PMID 23804577 ↗ · PMID 27496670 ↗ · PMID 28502045 ↗ · PMID 31751865 ↗ · PMID 33349335 ↗ |
| 疾病關聯 | SYNJ1 變異與 Developmental and epileptic encephalopathy 53（DEE53）相關。DEE53 是一種嚴重早發癲癇，具有癲癇發作難以控制、神經發育受損與預後不佳等特徵；發作前發育正常，發作後可出現認知與動作遲緩。此病以體染色體隱性方式遺傳，來源指出疾病由影響該基因的變異所致。 | 含實驗來源 | 證據與來源Developmental and epileptic encephalopathy 53 DEE53 A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE53 inheritance is autosomal recessive. The disease is caused by variants affecting the gene represented in this entry MIM: 617389 PMID 27435091 ↗ |
核酸與蛋白質序列
GGAAGTGACGCTCCCGGCGGCTGTGGCGGCGGCTGCGGGA40GAAGGAGGAGGAGGAGCCGGAGGAAGAGGGCTGCCTCCGA80AGAAAGGAGAATGGCGTTCAGTAAAGGATTCCGGATCTAT120CACAAATTGGATCCCCCACCTTTCAGCCTCATAGTGGAAA160CTAGGCATAAGGAAGAATGTCTCATGTTCGAGTCTGGGGC200TGTCGCTGTGCTCTCATCTGCAGAAAAAGAGGCAATCAAG240GGTACATACTCCAAAGTACTGGATGCATATGGACTCTTAG280GTGTTCTGCGGTTAAATCTTGGTGATACTATGTTACATTA320TCTGGTCCTAGTCACTGGATGTATGTCTGTTGGAAAAATT360CAAGAATCTGAAGTTTTCCGAGTTACTTCCACTGAGTTTA400TATCACTGCGAATCGATTCTTCAGATGAGGATCGCATTTC440AGAAGTGCGGAAAGTTTTGAATTCAGGAAACTTTTATTTT480GCATGGTCTGCATCTGGCATCAGTTTAGATTTGAGTCTTA520ATGCGCATCGTAGCATGCAAGAACAGACAACTGATAATAG560ATTTTTCTGGAATCAGTCTTTGCATTTGCATCTCAAACAC600TATGGCGTGAATTGTGATGACTGGTTATTACGTCTTATGT640GTGGAGGAGTAGAAATCAGAACAATTTATGCTGCTCATAA680ACAGGCGAAGGCTTGCCTCATTTCAAGATTAAGCTGTGAA720CGAGCTGGGACCAGGTTTAATGTCCGGGGAACAAATGATG760ATGGTCATGTTGCCAATTTTGTAGAAACAGAACAGGTTGT800GTACTTAGATGACTCAGTTTCTTCCTTCATACAAATCCGA840GGATCTGTTCCATTGTTCTGGGAGCAACCAGGGTTGCAAG880TGGGATCTCATCGTGTCCGTATGTCAAGGGGATTTGAAGC920CAATGCACCTGCTTTTGACAGGCATTTTAGAACACTTAAG960cDNA 使用 DNA 字母 T；mRNA 模式改以 U 顯示。轉錄本保留已註解的非編碼區，未另外加入 poly(A) 尾；非編碼 RNA 的參考轉錄本也可能仍需後續加工。數字為所選序列的 1-based 位置。長序列以黃色捲軸瀏覽，可複製或下載完整轉錄本與蛋白質；基因組 DNA 隨捲動取得所需範圍。